Ulrich Stangier Selected Research

Social Phobia

1/2020	Associations between movement synchrony and outcome in patients with social anxiety disorder: Evidence for treatment specific effects.
12/2019	Nonverbal synchrony predicts premature termination of psychotherapy for social anxiety disorder.
1/2018	Predictors of benzodiazepine use in a transdiagnostic sample of panic disorder, social anxiety disorder, and obsessive-compulsive disorder patients.
12/2017	Partner-related attachment as a moderator of outcome in patients with social anxiety disorder-a comparison between short-term cognitive-behavioral and psychodynamic therapy.
12/2016	Long-term cost-effectiveness of cognitive behavioral therapy versus psychodynamic therapy in social anxiety disorder.
2/2016	Facial discrimination in body dysmorphic, obsessive-compulsive and social anxiety disorders.
7/2015	Short-term cost-effectiveness of psychodynamic therapy and cognitive-behavioral therapy in social anxiety disorder: Results from the SOPHO-NET trial.
10/2014	Long-term outcome of psychodynamic therapy and cognitive-behavioral therapy in social anxiety disorder.
7/2014	Assessing treatment integrity in cognitive-behavioral therapy: comparing session segments with entire sessions.
7/2013	[Assessing common factors in psychotherapy: psychometric properties of a new time-economic instrument (WIFA-k)].

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ulrich Stangier Research Topics

Disease

16	Social Phobia 01/2020 - 07/2011
6	Post-Traumatic Stress Disorders (Post Traumatic Stress Disorder) 01/2023 - 01/2015
6	Body Dysmorphic Disorders (Body Dysmorphic Disorder) 01/2023 - 05/2008
2	Obsessive-Compulsive Disorder (Disorder, Obsessive-Compulsive) 01/2018 - 02/2016
2	Anxiety Disorders (Anxiety Disorder) 01/2018 - 03/2012
1	Cognitive Dysfunction 01/2023
1	Depressive Disorder (Melancholia) 07/2019
1	Dementia (Dementias) 07/2019
1	Prolonged Grief Disorder 01/2019
1	Panic Disorder (Panic Attack) 01/2018
1	Mood Disorders (Mood Disorder) 01/2015
1	Hypochondriasis 03/2012
1	Catastrophic Illness 03/2012
1	Pruritus (Itching) 09/2004
1	Atopic Dermatitis (Atopic Eczema) 12/2003
1	Psoriasis (Pustulosis Palmaris et Plantaris) 12/2003

Drug/Important Bio-Agent (IBA)

6	7,7'- dimethoxy- (4,4'- bi- 1,3- benzodioxole)- 5,5'- dicarboxylic acid dimethyl ester (BDD)IBA 01/2023 - 05/2008
4	2- cyclohexylidenhydrazo- 4- phenyl- thiazoleIBA 01/2023 - 01/2015
3	1-phenyl-3,3-dimethyltriazene (PDT)IBA 12/2017 - 01/2013
1	Prostaglandins DIBA 01/2019
1	BenzodiazepinesIBA 01/2018
1	pramoxine (pramocaine)FDA Link 05/2012
1	Indicators and Reagents (Reagents)IBA 03/2012
1	Immunoglobulin E (IgE)IBA 09/2004
1	SolutionsIBA 12/2003

Therapy/Procedure

18	Therapeutics 01/2023 - 12/2012
1	Home Nursing (Nursing, Home) 07/2019
1	Meditation 01/2015
1	Aftercare (After-Treatment) 07/2011